FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgaris

FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgaris image

The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology breakthrough is accomplished through a unique pulsing algorithm, integrated temperature monitoring, and precise automated control of the laser.

In the US alone, acne vulgaris affects more than 50 million teens and adults annually, making acne one of the most treated skin conditions by healthcare providers, with a market size of $4.27 billion in 2021.

"The Accure Laser System clearance is tremendously exciting for dermatologists and their patients. This platform is much more than the 1726nm wavelength laser that selectively targets sebaceous glands; this innovative intellectual property brings a new level of sophistication to energy-based devices targeting acne," says Christopher Carlton, Accure Acne Co-Founder, Chairman and CEO. "Accure Acne was founded over seven years ago to develop this disruptive technology to address multiple clinical applications. We have carefully built a positive safety profile and strive for best-in-class clinical results."

Accure's clinical and technical development teams represent an enduring collaboration of engineering acumen and clinical expertise, led by Prof. Rox Anderson, MD, Co-Founder and Chief Scientific and Medical Officer of Accure. Dr. Anderson is an influential medical scientist and inventor dedicated to the field of light and energy-based devices used in dermatology, medical aesthetics, and various specialties. Dr. Anderson says, "It has been my passion for two decades to bring lasting relief to acne sufferers throughout the world.  The Accure Laser System is a significant leap forward, and I congratulate Accure in achieving this important milestone. "

Fernanda Sakamoto, MD, PhD, the lead author of the seminal research of 1726nm laser wavelength selectivity of sebaceous glands adds, "My experience is that this is significant. Acne is such a common disease and many patients can fail treatment because of lack of compliance or contraindications to conventional medicines.  Having a new tool that can be used by a dermatologist in a controlled environment may improve the lives for so many patients."  

The lead clinician of the Accure Laser System's clinical development program is Emil A. Tanghetti, MD of The Center for Dermatology and Laser Surgery in Sacramento, CA. "We see compelling histological evidence of sebaceous gland damage at depths unique to this device's mechanism of action. The technology is tremendously sophisticated, yet elegantly simple to use.  I see this as a game-changer," says Dr. Tanghetti.

Accure is proud to partner with Quanta System, S.p.A., based in Milan, Italy, and a subsidiary of the El.En. Group in Florence, Italy. Quanta has contributed substantial ideas, resources and expertise to the development of the Accure Laser. Paolo Salvadeo, PhD, General Manager of El.En. Group, commented, "Quanta is known globally as a leader in engineering, design, quality and precision of laser manufacturing. We are proud to be integral to the development of the Accure Laser System and look forward to cooperating with Accure on this very innovative solution for inflammatory acne."

The company anticipates that the Accure Laser System will first be made available in a controlled, limited commercial release with selected board-certified dermatologists.  

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free